AUTHORS
Zhe Meng, Yabin Liu2, Bo Jiao, PhD3, Yun Tan, PhD4
AFFILIATIONS
1 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Background: Acute myeloid leukemia (AML) cells sustain high proliferative and transcriptional activity, creating an intrinsic risk of transcription–replication conflicts (TRCs). Such conflicts generate barriers to DNA replication and require dedicated tolerance mechanisms to prevent persistent replication stress and genome instability. Translesion synthesis (TLS) enables replication to proceed across otherwise replication-blocking obstacles, with REV1 serving as a central scaffold that coordinates specialized DNA polymerases at stalled replication intermediates. However, whether TLS machinery contributes to the tolerance of transcription-associated replication stress in leukemia remains largely unknown. We therefore investigated whether AML cells exploit REV1 as a TRC-buffering mechanism to sustain leukemia fitness.
Results: Pan-cancer transcriptomic profiling identified AML as a malignancy characterized by particularly high REV1 expression. Prompted by this observation, we interrogated multiple independent AML cohorts, including TCGA, BeatAML, TARGET, and an institutional Ruijin cohort, and consistently confirmed elevated REV1 expression in AML relative to normal hematopoietic counterparts. Moreover, REV1 expression positively correlated with somatic mutation burden, suggesting that AML cells experiencing increased genomic stress may acquire a greater requirement for REV1-mediated DNA damage tolerance. Consistent with this hypothesis, shRNA-mediated REV1 knockdown markedly impaired AML cell proliferation and resulted in coordinated downregulation of transcriptional programs controlling cell-cycle progression, DNA replication, and cell division.
To define how REV1 supports AML cells, we mapped its genome-wide chromatin occupancy by ChIP-seq. Strikingly, REV1 occupancy showed extensive overlap with RNA polymerase II (RNA Pol II), positioning REV1 at transcriptionally active chromatin where transcription and replication are most likely to interfere. We therefore investigated whether REV1 protects AML cells from transcription–replication conflicts (TRCs). REV1 knockdown caused a marked increase in proximity between proliferating cell nuclear antigen (PCNA) and RNA Pol II, as measured by proximity ligation assay, indicating accumulation of persistent encounters between the replication and transcription machineries. Together, these findings identify a spatial and functional link between REV1 and the transcription machinery and suggest that REV1 acts at transcriptionally active chromatin to limit endogenous TRCs.
To determine whether TRC buffering was linked to REV1-dependent translesion synthesis (TLS), we pharmacologically disrupted the REV1–REV7 interaction using JH-RE-06. JH-RE-06 phenocopied REV1 knockdown and similarly increased PCNA–RNA Pol II proximity, demonstrating that genetic and pharmacologic disruption of REV1 converge on the same TRC phenotype. These findings uncover an unexpected function of REV1-dependent TLS in buffering endogenous transcription–replication conflicts in AML. Functionally, disruption of this pathway impaired AML growth and enhanced sensitivity to venetoclax, revealing REV1-mediated TRC tolerance as a potentially actionable vulnerability in AML.
Conclusion: Our findings identify REV1-dependent translesion synthesis as a previously unrecognized mechanism that buffers endogenous transcription–replication conflicts in AML. REV1 is preferentially associated with transcriptionally active chromatin and limits persistent encounters between the replication and transcription machineries, thereby supporting leukemia cell proliferation under conditions of high transcriptional and genomic stress. These results reveal a distinct replication-stress tolerance dependency in AML and nominate REV1-mediated TRC buffering as a potential therapeutic vulnerability.
DISCLOSURES
Zhe Meng: No relevant conflicts of interest to declare.